Mostrar el registro sencillo del ítem

Secondary Stroke Prevention: A Population-Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence

dc.rights.licenseopenen_US
dc.contributor.authorFAURE, M.
dc.contributor.authorCASTILLOUX, A. M.
dc.contributor.authorLILLO-LE-LOUET, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEGAUD, Bernard
dc.contributor.authorMORIDE, Y.
dc.date.accessioned2021-01-25T10:34:55Z
dc.date.available2021-01-25T10:34:55Z
dc.date.issued2020
dc.identifier.issn1532-6535 (Electronic) 0009-9236 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/25978
dc.description.abstractEnUsing claims databases of a public healthcare program (Quebec) for the years 2010–2013, we conducted a cohort study of patients with acute ischemic stroke (AIS) to describe secondary prevention treatments and determine how they stood against practice guidelines. We compared the risk of death or AIS recurrence over 1 year in patients treated with anticoagulants, antiplatelets, and/or other cardiovascular drugs. In the month after discharge, 44.3% of the patients did not receive the recommended treatment and > 20% did not have any treatment. Untreated patients were younger, had less comorbidities, and a more severe AIS. Anticoagulants and antiplatelets were associated with a reduced risk of death or recurrence (hazard ratio (HR) 0.27; 95% confidence interval (CI) 0.20–0.36 and HR 0.25; 95% CI 0.16–0.38, respectively) compared with the untreated group. Effect size was similar for the other treatments. Findings confirm treatment benefits shown in clinical trials and emphasize the importance of AIS secondary prevention.
dc.language.isoENen_US
dc.subjectPharmacoEpi-Drugs
dc.title.enSecondary Stroke Prevention: A Population-Based Cohort Study on Anticoagulation and Antiplatelet Treatments, and the Risk of Death or Recurrence
dc.title.alternativeClin Pharmacol Theren_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1002/cpt.1625en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31502245en_US
bordeaux.journalClinical Pharmacology and Therapeuticsen_US
bordeaux.page443-451en_US
bordeaux.volume107en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue2en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03120031
hal.version1
hal.date.transferred2021-01-25T10:34:59Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Pharmacology%20and%20Therapeutics&rft.date=2020&rft.volume=107&rft.issue=2&rft.spage=443-451&rft.epage=443-451&rft.eissn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.issn=1532-6535%20(Electronic)%200009-9236%20(Linking)&rft.au=FAURE,%20M.&CASTILLOUX,%20A.%20M.&LILLO-LE-LOUET,%20A.&BEGAUD,%20Bernard&MORIDE,%20Y.&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem